Titlebook: Endocrine Therapies in Breast and Prostate Cancer; C. Kent Osborne Book 1988 Kluwer Academic Publishers, Boston 1988 carcinoma.cell.clinic

jettison

發(fā)現(xiàn)

Progestational Agents in the Treatment of Breast Cancer,s, which were the established hormonal agents used in patients with breast cancer at that time. Studies performed in the 1970s and early 1980s have demonstrated the effectiveness of progestins as secondary hormonal therapy for women with breast cancer, with response rates comparable to those of estr

notice

0927-3042 tegies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogue978-1-4612-8974-6978-1-4613-1731-9Series ISSN 0927-3042 Series E-ISSN 2509-8497

喃喃訴苦

adequate-intake

構(gòu)想

erythema

Aminoglutethimide: Theoretical Considerations and Clinical Results in Advanced Prostate Cancer,with advanced disease respond favorably to such initial therapy [2]. However, most responses to testicular androgen deprivation are incomplete and their duration is relatively short. The average time from initial androgen deprivation to further disease progression is one to two years [3].

楓樹(shù)

Effects of Estrogens and Antiestrogens on Cell Proliferation, agonists, and aromatase inhibitors such as amino-glutethimide presumably inhibit growth by reducing the concentration of estrogen available to the cancer cell. The nonsteroidal antiestrogens block the effects of endogenous estrogen at the cancer cell itself by competing with estrogen for its receptor.

JIBE

Book 1988ra- pies included surgical endocrine ablative procedures or pharmacologic hor- mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biolo

allude